PARSIPPANY, N.J., Aug. 23 Osteoarthritis (OA), the secondmost common diagnosis and leading cause of disability, is on the rise(1).This trend can have a substantial impact on managed care organizations andemployers -- in terms of costs from reduced productivity and medicaltreatment.
To address the issue and suggest alternative options and possiblesolutions, Ferring Pharmaceuticals launched the Ferring Managed Care TrendReport: Osteoarthritis, now available at no charge. Based on surveys andinterviews with hundreds of medical professionals and managed careorganizations, as well as data from published literature, this first-in-classreport presents a comprehensive overview of the issues and trends in thecoverage and treatment of osteoarthritis from the viewpoint of multiplestakeholders.
The Ferring-commissioned report presents the views of managed carepharmacy and medical directors, orthopaedic surgeons, rheumatologists, sportsmedicine and primary care physicians on delivering osteoarthritis treatment ina managed care environment. Results from original research surveys andinterviews with key stakeholder group members are discussed within the contextof industry trends that affect the delivery of care, and strategies that mayimprove treatment coverage. The 68-page report covers current trends amongemployers in managing costs of OA of the knee, trends among specialists inknee OA management, and reimbursement for viscosupplement/ hyaluronic acid(HA) products.
"Ferring developed the report to build awareness of the rising incidenceof OA and exhibit the financial impact of various treatment options formanaged care and employers," said William Garbarini, Executive Director, Salesand Marketing, Orthopaedics Business Unit at Ferring. "There are multipletreatment options for OA of the knee, such as HA therapy, and it is importantthat the industry take a look at how each of these treatments can play a rolein saving costs and employee productivity for employers. Using HA therapyearlier in the course of the treatment regimen may provide optimal, cost-effective results by delaying surgery."
The report was designed to help managed care organizations and employergroups answer questions such as: What is the financial impact of the rise inOA? How are various treatments reimbursed? Are there effective, less costlytreatments that will delay or eliminate the need for surgery? Are thesetreatments being used soon enough? The report also contains articles bymedical experts on OA treatment.
The free report is available exclusively through Ferring Pharmaceuticalcustomer account executives. To reach a customer account executive in yourarea, call 888-337-7464.
About Ferring Pharmaceuticals Inc.
Ferring Pharmaceuticals Inc., part of the Ferring Group, is a privatelyowned, international pharmaceutical company. Ferring's line of orthopaedicproducts includes EUFLEXXA(TM), hyaluronic acid for pain from osteoarthritisin the knee. Urology products include degarelix for prostate cancer (PhaseIII) and Minirin Melt for bladder dysfunction (Phase III).
Ferring also markets markets BRAVELLE(R) (urofollitropin for injection,purified), MENOPUR(R) and REPRONEX(R) (menotropins for injection, USP),Novarel(R) (chorionic gonadotropin for injection, USP) and ENDOMETRIN(progesterone) Vaginal Insert, 100 mg in the U.S. to infertility specialistsand their patients. Ferring also offers the Q.CAP(TM), the first and onlyneedle-free reconstitution device, for use with its fertility treatments.
Other products include ACTHREL(R) (corticorelin ovine triflutate forinjection) for the differential diagnosis of Cushing's syndrome andDESMOPRESSIN ACETATE in injectable and rhinal tube forms for the treatment ofdiabetes insipidus and primary nocturnal enuresis.
The Ferring Group specializes in the research, development andcommerciali